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Bone is a common location for breast cancer cell metastasis, and progression of tumor in bone 
can lead to bone loss and affect human health. Osteocytes have important roles in bone homeostasis 
and osteogenesis, and their interaction with metastasized cancer cells are known to affect 
progression of metastasized tumor. However, the potential role of metabolic signaling and actin-
cytoskeleton-associated moesin in the interaction of osteocytes and tumor cells remain poorly 
understood.  
In this study, we first examined the roles of metabolic signaling, specifically global AMPK 
modulators and mitochondria-specific AMPK inhibitor (Mito-AIP), as well as mechanical force 
in beta catenin signaling through interaction between osteocytes and precursor osteoblasts as well 
as osteocytes and breast cancer cells.  We also evaluated the role of metabolic signaling in Rho 
GTPases including RhoA, Rac1 and Cdc42. We observed that AMPK activator (A769662) and 
Mito-AMPK stimulated beta catenin translocation to the nucleus, indicating the activation of Wnt 
signaling, while Mito-AIP did not significantly affect beta catenin activation in osteoblasts. We 
also observed that osteocyte conditioned medium (CM) treated with Mito-AIP substantially 
increased beta catenin signaling in osteoblasts, while decreasing beta catenin signaling in breast 
cancer cells. CM of osteocytes treated with fluid flow increased beta catenin signaling in breast 
cancer cells. A769662 and Mito-AIP also decreased the activities of RhoA, Rac1, and Cdc42 in 
cancer cells which are known to regulate cancer cell migration. 
Additionally, we evaluated the roles of intracellular and extracellular moesin (MSN) protein 
in well-established oncogenic signaling proteins, such as FAK, Src, and RhoA as well beta catenin 
signaling. Constitutively active MSN (MSN+) significantly increased FAK and Src activities in 
cancer cells, but decreased the activity of RhoA. Surprisingly, CM of mesenchymal stem cells 
treated with MSN+ decreased the activities of FAK, Src, and RhoA, suggesting the inhibitory role 
of extracellular MSN in tumor-promoting signaling. Our results suggest the distinct role of AMPK 
signaling, specifically at mitochondria of osteocytes, in the activities of beta-catenin signaling in 
osteoblasts and breast cancer cells and the distinct role of intracellular and extracellular MSN in 







1.1. Cell Signaling  
There are multiple cell signaling pathways in the cell affecting cell function and fate. One 
of these important pathways is contractility pathway which gets involved in cell contraction, 
movement and response to mechanical force. The mechanical force gets sensed by cell surface 
receptor especially integrins as transmembrane proteins, and then transfers to the cytoskeleton [1]. 
Cytoskeleton components including actin filaments (F-actin), microtubule and intermediate 
filament get regulated by enzymes inside the cell especially Rho family of GTPases including 
RhoA, Rac1, CDC42 [Figure 1.1.]. In the force mechanotransduction, the mediator between 
integrin and cytoskeleton is focal adhesions. The force activates important enzymes in focal 





Figure 1.1. Signaling cascade from cell surface receptors such as integrin which activates FAK 






1.2. Cancer Cell Growth in Bone Environment 
In the ECM (extracellular matrix) of bone, OPN (osteopontin) is abundant which has a role 
in bone homeostasis. OPN amount in patients with breast cancer metastasized to the bone is higher 
than patients without this metastasis. Breast cancer and prostate cancer cells enhance expression 
of OPN in osteoblasts. Interaction of OPN with beta 1 integrin which is cancer cell surface receptor 
gives rise to activation of epidermal growth factor (EGF) which can promote proliferation of 
cancer cells. Therefore, OPN can prevent apoptosis and induce proliferation as well as adhesion 
of cancer cells  [4, 5]. Moreover, transforming growth factor beta (TGFb) can be another 
component in cancer cell growth. The exchange factor (TGFb) in bone matrix getting secreted 
during bone resorption which influences tumor growth. TGFb may interact with other factors in 
bone niche like hypoxia in bone marrow which can cause vascular endothelial growth factor 
(VEGF) expression leading to tumor growth [6]. When tumor metastasizes to bone, it can enhance 
osteoclast activity which can aggravate the growth and advancement of bone metastasis [7]. Also, 
calcium can be another component for cancer cells growth in the bone environment. Calcium is 
plentiful in the bone matrix and it can provoke breast cancer cells to inhibit apoptosis and promote 
proliferation [7, 8].  
1.3. Cancer Cell Migration to Bone Environment 
Cancer cells of origin tumor undergo different alteration to metastasize to another location 
in the body. In the first stage the cancer cells obtain invasive phonotype especially through 
epithelial to mesenchymal transition (EMT) leading to detachment of cancer cells. In the next 
stage, detached cancer cells invade stroma and then enter the blood flow called intravasation. Then, 
circulating tumor cells (CTCs) become stiffer due to resisting blood flow tension, but when they 
adhere to endothelial cells they become softer in order to penetrate to the target tissue called 
extravasation [Fig. 1.2.] [9, 10]. In the final stage, they colonize the target tissue and undergo some 







Figure 1.2. The steps of cancer metastasis including acquisition of invasive phenotype, 
intravasation, transmission in the blood, extravasation and colonization in the new tissue [9]. 
 
 
Vascularized areas of skeleton such as red marrow of long bones, pelvis, and vertebrae are 
the most common place for cancer cell migration leading to disrupting bone physiology, 
hematopoiesis and immune system [12]. As a matter of fact, breast cancer cells regularly migrate 
to the bone environment, and interrupts bone remodeling process, and they cause osteolysis by 
different factors such as matrix metalloproteinases (MMPs) [5]. Calcium in the bone matrix can 
be a strong chemoattractant to breast cancer cells. Breast cancer cells can express calcium sensing 
receptor (CASR) which can have a major role in breast cancer migration to the bone [7]. In 
addition, Cytokine RANKL (receptor activator of NF-kB ligand) which is osteoclast 
differentiation factor can be another strong agent in epithelial cancer cell migration to bone. Breast 
cancer cells can express RANK which can induce breast cancer migration to bone which binds 
RANKL [13]. Osteocytes can be another important breast cancer cells’ attractant through bone 
matrix proteins such as collagen and proteoglycans [14]. On the other hand, osteocytes and breast 
cancer cells interaction can have an advantageous role in inhibiting cancer cells migration. This 





1.4. Cytoskeleton of Osteocytes 
Osteocytes are responsible for responding to mechanical force in the bone as well as bone 
homeostasis, and include most portion of the bone. Mechanical loading is necessary for bone 
homeostasis and health, and it influence osteocytes. Osteocyte’s dendrites could connect to matrix 
through bone canaliculus, and this complex called collagen hillocks [16]. In osteocytes, focal 
adhesions (FAs) connect the cell membrane and matrix which is located between collagen hillocks 
and dendrites leading to mechanical force transfer to the cytoskeleton [Figure 1.3.]. Three major 
components of cytoskeleton of the cell are actin filaments (F-actin), microtubules and intermediate 
filaments, and F-actin plays an important role in osteocyte mechanoresponse. Therefore, inhibiting 
F-actin polymerization by drug affects cell contraction and morphology. On the other hand, 
microtubules influence calcium flow and expression of sclerostin as a bone formation inhibitor in 
the osteocyte. In other words, microtubules mediate opening of calcium channel by fluid flow 
shear stress leading to calcium flow to the cell. In addition, reactive oxygen species could be 
involved in sclerostin inhibition under fluid flow by microtubule network [17]. Suitable 
mechanical stress could prevent apoptosis and death of osteocyte leading to bone resorption due 
to expression of receptor activator of NF-kB ligand (RANKL) as well as osteoclastogenesis 
especially in old ages [18].  Wnt pathway is also important in mechanical response of osteocyte as 
well as bone homeostasis and mass [19]. Specifically, activation of Wnt signaling pathway and 
beta catenin translocation to the nucleus in osteocytes causes secretion of bone forming proteins 
including Osteoprotegerin (OPG) and OPN [20]. On the other hand activation of Wnt pathway can 







Figure 1.3. Osteocytes are in LCS of bone microenvironment, and it shows the components of 
osteocytes involved in mechano-response such as cytoskeleton, focal adhesions and ion channels 
[22]. 
 
1.5. The Role of AMPK in Cell Proliferation 
Abnormal, enhanced cell proliferation is one of the hallmarks of cancer [22]. Maintaining 
the proliferative state is energetically costly, requiring cellular energy. AMP-activated protein 
kinase (AMPK) is a primary signaling node that regulates cellular energy homeostasis by sensing 
the AMP to ATP ratio of the cell [23, 24].  It has been reported to suppress cell proliferation by 
inhibiting cyclin-dependent kinases through p53-p21 axis [25] and by inhibiting protein synthesis 
through the mammalian target of rapamycin (mTOR) pathway [26]. mTOR pathway has an 
important role in regulation of cell proliferation, growth and migration, and it can be unusually 
regulated in cancer cells; therefore, its inhibition by AMPK activation can restrain cancer cell 
growth [27]. When cells face the stress such as gene mutation leading to oncogene or lack of 
glucose results in p53 tumor suppressor activation [28, 29]. Glucose has an important role in cell 
cycle during proliferation, and lack of glucose causes p53 activation induced by AMPK [30]. 
Energy is necessary for cell division, and lack of energy activates AMPK leading to the cell cycle 





AMPK pathway during tumor cell division resulting in cancer cell proliferation with nutrient 
deficiency; therefore, AMPK activation can be a suitable method for cancer therapy [31, 32] .   
1.6. The Connection Between AMPK and Rho Family GTPases 
AMPK have an important role in cell contraction which is mediated by Rho GTPases. Rho 
GTPases have major role in different types of cell migration by generating traction forces. AMPK 
can be employed in cadherin adhesion process in order to provide energy and increase ATP for 
strengthening adhesion as well as cytoskeleton rearrangement leading to withstanding forces. 
From another angle, in the contractility pathway as well as E-cadherin adhesion, AMPK activates 
Abl (Abelson tyrosine kinase) which causes phosphorylation of  Tyr822 vinculin culminating in 
RhoA GTPase activation. Therefore, AMPK is required to elevate contractility through RhoA 
activation when E-cadherin experiences the force [33]. In addition, AMPK can be employed in the 
junctions of cells in order to cell-cell adhesion. AMPK inhibition hinders phosphorylation of Abl, 
GTP-loading of RhoA, and myosin II; thus, AMPK acts as an upstream regulator of contractility 
in cell-cell adhesion [1]. In contrast, AMPK inhibition by compound C can activate Rac1 and 
Cdc42 Rho GTPase proteins in microglia cells which are central immune cells in nervous system 
leading to actin rearrangement in order to cell migration [34].  
RhoA-myosin II contractility pathway employ AMPK to provide ATP by glycolysis for cell 
contraction. When E-cadherin experiences forces, it can be transduced to the RhoA-ROCK-myosin 
II pathway leading to cell contraction. Hence, this contractility pathway activates AMPK in order 
to providing intracellular ATP preventing cell detachment when the cell is under forces, and 
inhibition of myosin II reduces AMPK activation [35]. On the other hand, in the other study it is 
observed that inhibition of ROCK (Rho associated protein kinase) can improve metabolic disease 
by activating AMPK. ROCK is the effector protein of RhoA in contractility pathway which has 
high activity in people with metabolic diseases such as obesity; therefore, inhibition of ROCK is 
advantageous for improvement of these diseases. Inhibition of ROCK can up-regulate some 
molecular components relating to energy generation by mitochondria, fatty acid oxidation and 
glucose transporting which are downstream molecules of AMPK leading to higher AMPK activity 





1.7. The Role of AMPK in Bone Cells  
Osteoblast cells have an important role in bone formation, and they control the mineral 
deposition such as calcium in the bone, and mineral lacking can lead to osteoporosis disease [37]. 
Consuming saturated fatty acids such as palmitate can reduce mineral density by prompting 
osteoblast apoptosis [38]. On the other hand, AMPK as a metabolic enzyme is sensitive to the cell 
energy level and in low energy level in the cell it causes ATP generation by fatty acid oxidation 
[39]. Hence, AMPK activation can prevent osteoporosis caused by palmitate through inhibition of 
osteoblast apoptosis as well as fatty acid oxidation [40]. In addition, it is observed that Metformin 
as an AMPK activator drug can cause the expression of bone morphogenetic protein-2 (BMP-2) 
as well as endothelial nitric oxide synthase (eNOS) in osteoblast precursor cells (MC3T3 cells) 
which is in favor of differentiation of MC3T3 cells to osteoblast and bone formation [41]. 
Moreover, AMPK activator such as Metformin can cause MC3T3 cells differentiation through 
another pathway including Dlx5 and Runx2 which are transcription factors for osteogenesis [42]. 
It is also observed that inhibition of AMPK in mice is against bone formation and it also stimulates 
the osteoclast activity and bone resorption [43, 44]. In addition, AMPK could be involved in 
osteogenesis by affecting Wnt signaling pathway. Specifically, bone development treatment such 
as using Naringin employs AMPK for activation of Wnt signaling and Beta catenin protein 
translocation to the nucleus in MC3T3 cells leading to bone formation [45].   
Osteocytes have the main role in regulating bone formation and resorption by cell signaling 
connection with osteoblasts and osteoclasts in the bone [46]. Osteocytes as a master regulator of  
bone cells can make communication with osteoblasts by transmitting signals and secreting soluble 
factors such as fibroblast growth factor (FGF) through lacuna-canalicular system (LCS) which is 
porous structure enclosing osteocytes [47]. Therefore, soluble factors and biochemical molecules 
released from osteocytes can be transmitted to osteoblasts through LCS which can cause their 
proliferation and differentiation [48]. It is also observed that AMPK influences receptor activator 
of NF-kB ligand (RANKL) and sclerostin expressions in osteocytes which are osteoclast 
differentiation factor and bone formation suppressor [49-51]. Particularly, AMPK activator 
notably decreases RANKL expression, and also initially sclerostin expression rises under AMPK 
activator, but then it starts to decrease after a day; therefore, the AMPK effect on sclerostin could 





Osteoprotegerin (OPG) expression which is osteoclastogenesis inhibitory factor in mice osteocytes 
[52]. In addition, AMPK activation could hinder apoptosis of osteocyte cells by high homocysteine 
(Hcy) in blood plasma which is an important reason for osteoporosis [53, 54].  
1.8. The Role of Mitochondrial AMPK in Overall Cell Behaviors 
  AMPK can mainly regulate mitochondrial biogenesis when the energy chronically has 
diminished [55, 56]. AMPK has a role in autophagy which is degradation process in order to 
provide energy when there is lacking in nutrients. Hence, in critical circumstances such as 
mitochondrial stress AMPK gets activated and removes selectively impaired mitochondria through 
autophagy. As a matter of fact, continuous cancer cell survival can be caused by inspection of 
impaired mitochondria as well as preventing intrinsic apoptosis owing to mitochondrial AMPK. 
As a result, mitochondrial AMPK can cause changes in mitochondria through ATG5 (autophagy 
related 5)  [57]. Mitochondrial AMPK can also have a role in preserving homeostasis in cell 
metabolism. ROS (reactive oxygen species) has the role in cell metabolic balance, and 
mitochondria is the principle producer of it. Mitochondrial reactive oxygen species (mROS) can 
activate AMPK which decreases mROS production as a feedback and decreases cell damage 
induced by ROS. Moreover, many cancer cells have high amount of ROS inducing cancer cell 
growth; therefore, combination of mitochondrial AMPK and mROS can have a role in inhibiting 
tumor growth by decreasing ROS amount [58].  
Mitochondria biogenesis regulated by AMPK activation can encourage cancer cell 
proliferation and migration. When there is lacking in glucose in cancer cells, mitochondrial 
biogenesis rises affected by AMPK activation. In other words, mitochondria biogenesis elevation 
is in favor of oxidative metabolism and preserving energy for cell metabolism as well as 
proliferation [59]. In addition, mitochondrial AMPK can inhibit cancer cell growth and 
proliferation. Mitochondrial AMPK can reduce glycolysis rate and increase oxidative 
phosphorylation in cancer cells. Glycolysis is the major energy supply to cancer cells, and its rate 
is much higher than normal cells which is beneficial for cancer cell proliferation and migration 
through providing acidic environment for cancer cells and activation of matrix metalloproteinases 
respectively. As a result, mitochondrial AMPK can inhibit cancer cell proliferation and migration 





leading edge of cell influenced by AMPK, and this causes local ATP accumulation in the leading 
edge of cell in favor of cytoskeletal dynamics and cell migration. As a result, inhibition of 
mitochondrial AMPK may disrupt cancer cell migration [61, 62].  
1.9. The Role of Mitochondrial AMPK in Bone Cells and Osteogenesis 
Mitochondria can promote AMPK activity by production of reactive oxygen species (ROS) 
during the environmental stress such as hypoxia [58]. On the other hand, AMPK activation can 
increase the activities of enzyme in the mitochondria especially mitochondrial oxidative enzyme 
such as mitochondrial AMPK, and biogenesis of mitochondria in rat skeletal muscle [63] [64]; 
therefore, AMPK elevates oxidative metabolism through mitochondrial biogenesis [59].   
Mitochondria as a cell energy source can have an important role in cell differentiation as well as 
apoptosis [65]. Osteoblastic differentiation can be accompanied by mitochondrial biogenesis and 
its mass increase [66]. Also, mitochondrial-derived peptide MOTS-c treatment increases 
OPG/RANKL ratio in the osteocytes in favor of inhibiting osteolysis [52]. In addition, this 
mitochondrial peptide inhibits osteoclastogenesis as well as osteoporosis through AMPK 
activation, and specifically AMPK inhibition hinders the effect of MOTS-c [67].     
1.10. The Role of Mechanical Stress in Osteocytes and Osteogenesis 
Mechanical stress including fluid flow in bone canaliculus has a major role in bone 
remodeling as well as homeostasis [68]. Osteocytes are the mechanosensory bone cells that affect 
the bone formation and osteogenesis by controlling osteoblastic differentiation through Wnt 
signaling pathway [14, 69]. In other words, Wnt pathway activation causes the accumulation of 
beta catenin protein in the nucleus of osteoblast leading to differentiation of precursor osteoblast 
(pre-osteoblast) cells as well as bone formation [70]. Therefore, osteocytes under mechanical stress 
secrete Wnt growth factors influencing pre-osteoblast cells through LCS [71]. Besides, Wnt/Beta 
catenin pathway activation can prevent the osteocytes apoptosis in bone tissue. Particularly, fluid 
flow causes opening of gap junction channels (hemichannels) in connected osteocytes leading to 
ATP release and Calcium increase in osteocytes preventing their apoptosis [72]. Mechanical force 
can transmit to the cytoskeleton of osteocytes through connection among extracellular matrix 





reorganization [73, 74]. On the other hand, eliminating mechanical force causes osteocytes 
hypoxia and hemostasis disruption affecting osteocyte apoptosis [75]. Also, mechanical stress on 
osteocytes can induce autophagy which degrades and recycles cellular components needing 
AMPK activation [76]. 
Mechanical stress affects AMPK activity and localization in the cell because of balancing 
energy and oxygen level of the cell [61, 77]. Also, gene ontology a bioinformatics method has 
revealed that AMPK is one of top canonical signaling pathway in the osteocyte under fluid flow 
stress [78]. Moreover, mechanical cyclic stretch of bone marrow derived mesenchymal stem cell 
elevates the phosphorylation of AMPK causing osteogenic differentiation, and on the other hand 
inhibition of AMPK abolishes the effect of mechanical stress in favor of osteogenesis [79]. 
1.11. Role of Moesin in Cytoskeleton and Cancer Progression 
ERM protein family includes three proteins ezrin, radixin and moesin (MSN) located in cell 
membrane and especially adherens junction. ERM upregulation in epithelial cells causes apical 
microvilli formation as well as adherent junction stability, and also Rho kinase can lead to 
activation of ERM in most of the cell types [80]. Moreover, ERM proteins have a considerable 
role in actin arrangement through crosslinking between actin and membrane proteins and 
phospholipids. Particularly, ERM could be both upstream such as involving in stress fiber and 
downstream regulator of RhoA GTPase [81]. In immune cells such as T and B cells and 
neutrophiles MSN is the dominant protein of ERM family, and inhibits the activation of Rho 
GTPase, so inhibiting MSN causes upregulation of Rho GTPase , and abnormal cell spread and 
polarization leading to flaw in capturing microorganisms and pathogens [82]. In addition, MSN 
has a crucial role in microglia’s cytoskeleton which is the main immune defender in central 
nervous system (CNS), and it affects the function, migration and morphology of microglia through 
interaction with Rho family of GTPases including RhoA, Rac1, Cdc42 [83]. Also, MSN could 
have a function in mitotic cell division due to binding to microtubules in the cytoskeleton [84]. On 
the other hand, MSN expression could affect epithelial to mesenchymal transition (EMT) of 
epithelial cells through actin reorganization and changing location of contractile components such 
as alpha- smooth muscle actin (α-SMA). It is also observed that inhibition of MSN disrupt cell 





alters actin organization as well as contraction components such as α-SMA inducing EMT in 
epithelial cells [85]. Moreover, MSN expression similar to Snail expression is related to EMT of 
breast cancer especially invasive ductal carcinoma which could be a biomarker in early detection 
of cancer [86]. In breast cancer cell, Rho association protein kinase (ROCK) activates MSN 
leading to expression of programmed cell death ligand (PD-L1) which is an immune checkpoint 
inhibitor causes evasion of cancer from immune system attack and difficulty in cancer detection. 
Thus, either ROCK inhibition or MSN silencing can downregulate PD-L1 expression leading to 
penetration of immune cells in favor of cancer treatment [87].  
1.12. FRET Imaging  
Fluorescent resonance energy transfer (FRET) microscopy is a method for imaging and 
discovering the subcellular proteins activities. FRET biosensors include donor and accepting 
fluorescent proteins that can change their conformation. The donor protein is cyan fluorescent 
protein (CFP), and the acceptor is yellow fluorescent protein (YFP). In RhoA biosensor, CFP and 
YFP get close to each other when the enzyme is getting activated. Hence, the biosensor emits high 
YFP signal and low CFP in the active state, so the FRET ratio could be calculated by the ratio of 
FRET YFP/FRET CFP [Fig. 1.4.]. On the other hand, in Src and FAK mechanism is reverse and 
FRET ratio equals to ratio of FRET CFP/FRET YFP.  In addition, in the active state there are CFP 
excitation and YFP emission with wavelengths of 433 nm and 527-530 nm respectively[88].   
 
Figure 1.4. FRET signaling in activation of RhoA GTPase in which fluorescent proteins get to 








2.1. Biosensors and Plasmids 
FRET (fluorescence resonance energy transfer) biosensors including Src, FAK, Rho family 
of GTPases , Rac1, CDC42 and AMPK were used for transfection leading to observation of 
subcellular activities of the cell. Src and FAK biosensors were composed of a cyan fluorescent 
protein (CFP) connected to a yellow fluorescent protein (YFP) [89, 90]. Rho family of GTPases 
plasmids including RhoA, Rac1, CDC42 were composed of CFP and YFP in which intramolecular 
binding of kinase to the binding domain of an effector protein causes proximity of CFP with YFP 
leading to FRET elevation from CFP to YFP [91]. AMPK biosensors divided to Cyto-AMPK and 
Mito-AMPK included CFP, an FHA1 binding domain, an AMPK substrate peptide and YFP. Also, 
mitochondrial AMPK inhibitor peptide (Mito-AIP) was used for specific inhibition of Mito-
AMPK [92]. In addition, MSN SiRNA and constitutively active MSN were used for inhibition and 
activation of MSN.  
2.2. Chemical Reagents 
A769662 as AMPK activator with 25 µM concentration and compound C as AMPK inhibitor 
with 5 µM concentration were used. Also, Y-27632 as ROCK inhibitor with concentration of 10 
µM was used.  
2.3. Cell Culture and Transfection 
Culture of four cell types including human breast cancer cell (MDA-MB-231), osteocyte 
(MLO-A5), precursor osteoblast (MC3T3) and mouse mesenchymal stem cell (MSC). 89% 
dulbecco's modified eagles medium (DMED, Lonza) plus 10% fetal bovine serum (FBS, Gibco) 
plus 1% penicillin (Lonza) were used to for cancer cells culture. On the other hand, 89% minimum 
Essential Medium α (MEM α, Gibco) plus 5% FBS (Gibco) plus 5% bovine calf serum (BCS, 
Gibco) plus 1% penicillin (Lonza) were used for osteocytes culture. In addition, combination of 
89% minimum Essential Medium α (MEM α, Gibco) plus 10% FBS (Gibco) plus 1% penicillin 





(Cell Biologics) plus 10% FBS (Gibco) plus 1% penicillin (Lonza) were used for MSC culture. 
All cells were maintained in 37 degree of Celsius and 5% CO2 in the humid incubator. For 
transfection of cells two methods of chemical reagent and electroporation were used. In chemical 
transfection, Lipofectamine 2000 was used, and cells got incubated for at least 4 hours in OPTI-
MEM (Gibco) media without serum and antibiotic. Then, transfection medium with 5% FBS was 
added to cells for long time incubation, and cells became transfected 24 hours before imaging. 
Osteocytes and pre-osteoblasts transfections were done by electroporation. In electroporation 
method with Neon device (Thermo Fisher), the cells became suspended in buffer R, and then cell 
solution in 10 µl tip was inserted into Neon tube including 3 ml buffer E. The settings of device 
for electric shock for bone cells were 1200 Volt, 20 ms, 1 pulse, and after shock transfected cell 
solution became transferred to the transfection media with 5% FBS and without antibiotics.  
2.4. Condition Medium (CM) Experiments 
We followed four different protocols for CM of osteocytes experiments. First protocol was 
for CM without any modulators. In the first day we cultured and grew of osteocytes, and in the 
second day we changed the osteocyte media with transfection media including 2% FBS, 99% 
MEM alpha (condition media). In the third day we did transfection of either cancer or pre-
osteoblast cells with beta catenin and transferred condition media to the cells 3 hours after 
transfection. In the last day we did imaging of beta catenin activity of the cells with condition 
media.  
Second protocol was for double transfection treatment of osteocytes like Mito-AIP. After 
growing the cells, in the first day we transfected osteocytes with specific DNA vector like Mito-
AIP (media1). In the second day we transfected either osteocyte or cancer cells with beta catenin. 
In the third day we replaced CM, and after 6 hours started imaging.  
Third protocol was for drug treatment of osteocytes. After growing cells, in the first day 
we did transfection of cancer cells with beta catenin, and add AMPK modulator drug to 
osteocyte dish and incubated for 24 hours. In the second day, we transferred CM to the cells, and 






2.5. Shear Stress Application 
For mechanical stimulation of cells, µ-slide cell culture chambers (Ibidi) were used [Fig. 
2.1.A]. We used cyclic flow device with frequency of 1 Hz exerting 12 dyn/cm2 shear stress [Fig. 
2.1.B]. Also, Unidirectional fluid flow imposing 10 dyn/cm2 was used for flow induction 
simultaneous with imaging [Fig. 2.1.C]. On the other side, the sterile tubing was connected to the 
chamber and transfection media flows inside the tubing. 
 
Figure 2.1.  (A) Image of the µ-slide cell culture chamber connecting to the tubing. (B) The 
experimental set-up for cyclic flow experiment. (C) The experimental set-up for unidirectional 








2.6. Microscopy and Image Analysis 
Nikon Ti-E inverted microscope plus EMCCD camera (Photometrics, Evolve 512) and 
perfect focus system (PFS, Nikon) were used for imaging. In FRET imaging the wavelengths of 
CFP excitation, CFP emission and YFP emission are 438, 488 and 542 respectively. In addition, 
the wavelength of GPF emission was 522.5 for capturing green fluorescent image. Analysis of 
FRET ratios of subcellular components were done by NIS-element software (Nikon), and GFP 
images were made by ImageJ software.  
2.7. Statistical Analysis  
All data were analyzed with standard error of mean (SEM), and the graphs are plotted by 
GraphPad Prism 5 software. Statistical significance between two groups in column bar graphs was 
assessed with student’s t-test, and a p-value lower than 0.05 shows statistically significance. In 
addition, one-way-analysis of variance (ANOVA) followed by Dunnett's post hoc test was used 



















3.1. Role of AMPK Modulators on Osteogenesis and Tumor Suppression 
Beta catenin translocation to the nucleus was one of the important signs in bone formation 
and osteogenesis. Increasing beta catenin activity in the nucleus of pre-osteoblast (MC3T3) cells 
was an important factor for osteoblast differentiation as well as bone formation. In addition, beta 
catenin activity and Wnt signaling in osteocytes which were the bone mechanosensory cells can 
be important in bone formation. We evaluated beta catenin translocation in osteocytes and pre-
osteoblast cells cultured in collagen coated glass dishes under AMPK modulators [Fig. 3.1.]. 
AMPK activator affected Wnt signaling pathway in osteocyte cells (MLO-A5) and increased beta 
catenin activity in the nucleus 10% in 2 hours although it did not increase beta catenin translocation 
in the first 1 hour [Fig. 3.1.A]. On the other hand AMPK inhibitor did not affect the nucleus activity 
of the beta catenin within 2 hours [Fig. 3.1.B]. Moreover, inhibition of mitochondrial AMPK in 
the osteocyte increased the beta catenin basal activity in the nucleus 80% [Fig. 3.1.C]. 
We conducted experiments for observing the role of AMPK modulators and mitochondrial 
AMPK in beta catenin activity in pre-osteoblast cells and osteocytes. Both cells transfected with 
Beta catenin biosensor were plated in glass dishes coated with collagen, and for inhibition of 
mitochondrial AMPK (Mito-AIP) the cells became double transfected with beta catenin and Mito-
AIP. Using AMPK activator (A 769662) increased the beta catenin translocation to the nucleus in 
pre-osteoblast cells, and it slowly elevated beta catenin activity in nucleus (15% increases in 2 
hours) [Fig. 3.1.D]. Using AMPK inhibitor (compound C) did not alter the beta catenin activity in 
the nucleus of pre-osteoblast cells within 2 hours [Fig. 3.1.E]. Unlike global AMPK inhibitor, 
mitochondrial AMPK inhibitor (TOM-20mchf-AIP) did not affect the beta catenin basal activity 






Figure 3.1. Effects of AMPK modulators on beta catenin activity of osteocytes and osteoblasts; 
color bar of images represents GFP signaling; scale bar=10 µm; * p<0.05, ** p<0.01. (A) The 
bar graphs of beta catenin activity in the nucleus of osteocytes after 1 and 2 hours treatment with 
AMPK activator; n=14. (B) The bar graph of beta catenin activity in the nucleus of osteocytes 
after 1 and 2 hours treatment with AMPK inhibitor; n=12. (C) The bar graph of beta catenin 
basal activity in the nucleus of osteocytes in control and transfected with Mito-AIP; n=11. (D) 
The bar graphs of beta catenin activity in the nucleus of pre-osteoblasts after 1 and 2 hours 
treatment with AMPK activator; n=16. (E) The bar graph of beta catenin activity in the nucleus 
of pre-osteoblasts after 1 and 2 hours treatment with AMPK inhibitor; n=12. (F) The bar graph of 
beta catenin basal activity in the nucleus of pre-osteoblasts in control and transfected with Mito-
AIP; n=10. 
 
We also set up experiments to evaluate the connection between osteocytes and pre-
osteoblasts. Specifically, we evaluated the effect of conditioned medium (CM) of osteocytes with 
AMPK modulators on basal beta catenin activity in pre-osteoblast cells. At first, adding CM to 
pre-osteoblast cells (b) increased beta catenin basal activity in the nucleus (30% increase) 
comparing to normal media (a) of pre-osteoblasts. AMPK inhibition and activation in osteocytes 
affected the CM as well as pre-osteoblast cells. Applying AMPK activator to osteocytes CM (c) 
increased beta catenin basal activity in the nucleus of pre-osteoblast cells including 60% increase 
comparing to normal media and 30% increase comparing to CM without AMPK modulators. Also, 






and this treated CM increased beta catenin basal activity in the nucleus (70% increase) of pre-
osteoblast cells.  
In contrast, applying AMPK inhibitor to osteocytes (e) did not alter beta catenin basal 
activity comparing to CM without AMPK modulator, but its activity was higher than normal media 
(30% higher).  Moreover, AMPK activation and inhibition in pre-osteoblasts in the presence of 
CM affected beta catenin basal activity on them. Applying AMPK activator to pre-osteoblasts with 
CM (f) increases beta catenin basal activity in the nucleus comparing to CM without AMPK 
modulators (20% increase) and normal media (50% increase). On the other hand, applying AMPK 
inhibitor to the pre-osteoblasts with CM (g) decreased beta catenin basal activity in the nucleus of 
pre-osteoblast (20% decrease) comparing to CM without AMPK modulators, and increased its 
activity (10% increase) comparing to normal media. Therefore, Inhibition of mitochondrial AMPK 
in osteocytes caused the highest increase in beta catenin basal activity in nucleus of pre-osteoblast 
cells through affecting CM of osteocytes. Conversely, AMPK inhibitor caused the highest decrease 
in beta catenin activity in CM comparing to CM without AMPK modulators. Also, CM improved 
the effects of AMPK activator and inhibitor on beta catenin translocation to the nucleus of pre-
osteoblast cells, because AMPK modulators did not affect beta catenin activity in pre-osteoblasts 
with normal media [Fig. 3.2A]. 
We set up experiments to evaluate the connection between osteocytes and metastasized 
cancer cells. Specifically, we evaluated the effect of conditioned medium (CM) of osteocytes 
treated with AMPK modulators on basal beta catenin activity in cancer cells. At first, adding CM 
to cancer cells (b) decreased beta catenin activity in the nucleus (30% decrease) comparing to 
normal media (a) of pre-osteoblasts. Also, AMPK inhibition and activation in osteocytes affected 
the CM as well as cancer cells. Applying AMPK activator to osteocytes CM (c) slightly increased 
beta catenin activity in the nucleus (4% increase). Also, mitochondrial AMPK inhibition (Mito-
AIP) of osteocytes (d) significantly decreased beta catenin basal activity in the nucleus (40%) in 
cancer cells. Applying AMPK inhibitor to osteocytes (e) reduced beta catenin activity 6% in the 
nucleus comparing to CM without AMPK modulator. In addition, AMPK activation and inhibition 
in cancer cells in the presence of CM affected beta catenin basal activity on them. Applying AMPK 
activator to cancer cells with CM (f) decreased beta catenin basal activity in nucleus 14%. 
Applying AMPK inhibitor to the pre-osteoblasts with CM (g) did not change beta catenin basal 





Therefore, Inhibition of mitochondrial AMPK in osteocytes caused the highest increase in 
beta catenin basal activity in nucleus of pre-osteoblast cells and highest decrease in beta catenin 
basal activity in nucleus of cancer cells through affecting CM of osteocytes. Conversely, AMPK 
inhibitor caused the highest decrease in beta catenin activity in CM comparing to CM without 
AMPK modulators. Also, CM improved the effects of AMPK activator and inhibitor on Beta 
catenin translocation to the nucleus of pre-osteoblast cells, because AMPK modulators did not 




















Figure 3.2. Effect of CM of osteocytes treated with AMPK modulators on beta catenin activity of 
cancer cells and pre-osteoblasts; *, #, $, & p<0.05, **, ## p<0.01, ***, ### P<0.001; scale 
bar=10 µm. (A) beta catenin activity in nucleus of pre-osteoblasts. (B) beta catenin activity in 
nucleus of cancer cells. 
 
We also evaluated effects of AMPK modulators in Rho family GTPases including RhoA, 
Rac1 and Cdc42 in cancer cells, and also we did time course experiment for 1 hour for drug 





8%, 30% and 11% respectively [Fig. 3.3.A-C]. On the other hand, AMPK inhibitor (Compound 
C) did not change the activity of these kinases in cancer cells [Fig. 3.3.D-F]. In addition, Mito-AIP 
treatment of cancer cells reduced basal activities of RhoA, Rac1 and Cdc42 12%, 9% and 6% 
respectively [Fig. 3.3.g-I]. So, inhibition of mitochondrial AMPK caused similar effect of AMPK 
activator in cancer cells, and both decreased activity of cytoskeleton related kinases which are 








Figure 3.3. The effects of AMPK modulators on Rho family GTPases of breast cancer cells; 
color bar represents FRET ratio. (A) Time course graph showing FRET ratio of RhoA with 1 
hour AMPK activator treatment in t=0; n= 18; scale bar= 10 µm. (B) Time course graph showing 
FRET ratio of Rac1 with 1 hour AMPK activator treatment in t=0; n= 14; scale bar= 10 µm. (C) 
Time course graph showing FRET ratio of CDC42 with AMPK activator treatment in t=0; n= 13; 
scale bar= 10 µm. (D) Time course graph showing FRET ratio of RhoA with AMPK inhibitor 
treatment in t=0; n= 11; scale bar= 10 µm. (E) Time course graph showing FRET ratio of Rac1 
with AMPK inhibitor treatment in t=0; n= 11; scale bar= 20 µm. (F) Time course graph showing 
FRET ratio of CDC42 with AMPK inhibitor treatment in t=0; n= 13; scale bar= 10 µm. (G) The 
graph bar showing FRET ratio of RhoA with Mito-AIP treatment ; n= 18; scale bar= 20 µm. (H) 
The graph bar showing FRET ratio of Rac1 with Mito-AIP treatment ; n= 14; scale bar= 10 µm. 
(I) The graph bar showing FRET ratio of CDC42 with Mito-AIP treatment ; n= 17; scale bar= 10 





3.2.  Role of Fluid Flow Stress on Osteocytes and Cancer Cells  
Mechanical force plays an important role in cytoskeleton components rearrangement 
including microtubule assembly and actin polymerization. Therefore, when the cell does not 
experience mechanical force, the cytoskeleton would not make contraction force needing energy 
consumption. We conducted the experiments to observe the role of AMPK in the cytosol and 
specifically in the mitochondria of osteocytes with fluid flow. Osteocyte cells (MLO-A5) 
transfected with cytosolic AMPK (Cyto-AMPK) biosensors were plated in two different flow 
chambers coated with collagen. Then, during the imaging they were exposed to continuous fluid 
flow imposing 10 dyne/cm2 shear stress similar to physiological condition. During 1 hour 
experiment, fluid flow increased Cyto-AMPK activity 35% and Mito-AMPK activity 12% in 
osteocytes [Fig. 3.4 A,B]. Moreover, we evaluated the connection between AMPK and 
cytoskeleton in osteocytes. Specifically, We treated osteocytes with the inhibitor of Rho-associated 
protein kinase (ROCK) with 1 hour incubation before imaging. In the experiment, fluid flow did 
not increase Cyto-AMPK activity, so ROCK could be an upstream regulator of AMPK [Fig. 3.4 
C]. On the other hand, we evaluated the effect of CM of osteocytes treated with cyclic flow on 
beta catenin activity of metastasized cancer cells [Fig. 3.4D]. In other words, we exposed cyclic 
flow with frequency of 1 Hz causing 12 dyne/cm2 shear stress on osteocytes, and then transferred 
the treated CM to cancer cells 12 hours before imaging. We observed that flow treated CM 
significantly increased beta catenin translocation to the nucleus of cancer cells (35% increase) 
which shows the negative effect secreted soluble factors of osteocytes under flow on metastasized 






Figure 3.4. Fluid flow effects; scale bar= 10 µm. (A) The effect of 1 hour fluid flow on FRET 
ratio of Cyto-AMPK in osteocytes; color bar represents FRET ratio (FRET YFP/FRET CFP) (B) 
The effect of 1 hour fluid flow on FRET ratio of Mito-AMPK in osteocytes; color bar represents 
FRET ratio (FRET YFP/FRET CFP). (C) The effect of 1 hour fluid flow on FRET ratio of Cyto-
AMPK in osteocytes treated with Y-27632; color bar represents FRET ratio (FRET YFP/FRET 
CFP). (D) Beta catenin basal activity in cancer cells in CM of osteocytes treated with cyclic 
flow; color bar represents GFP signal; *** p<0.0001. 
 
3.3.  Role of MSN Modulators on Osteocytes and Cancer Cells 
We evaluated the roles of MSN SiRNA (MSN-) and constitutively active MSN (MSN+) in 
contractility pathway of osteocytes and metastatic breast cancer cells to the bone including focal 
adhesion kinase (FAK), RhoA GTPase and Src (Proto-oncogene tyrosine-protein kinase). We 
observed different responses of these kinases to MSN treatment in osteocytes and breast cancer 
cells [Fig. 3.5.]. MSN silencing transfection in osteocytes reduced RhoA and Src basal activities 
9% and 3% respectively, but conversely it increased FAK basal activity 6%.  On the other hand, 
transfection of osteocytes with MSN+ plasmid increased RhoA and Src activity 10% and 32% 





Src had similar behavior to intracellular MSN modulators. In the breast cancer cells (MDA-MB 
231), transfection silencing of MSN decreased FAK and Src basal activity 5% and 7% 
respectively, and it did not change RhoA activity. On the other side, transfection of cancer cells 
with MSN+ increased FAK activity 30% and Src activity 50%, and decreased RhoA activity 10% 
[Fig. 3.5.D-F]. Therefore, in cancer cells FAK and Src had similar behavior to intracellular MSN 
modulators. In addition, in cancer cells and osteocytes FAK and RhoA had opposite response to 
intracellular MSN modulators, but Src had the same behavior. Therefore, MSN acts differently in 




Figure 3.5. Role of intracellular MSN in osteocytes and cancer cells; color bar represent FRET 
ratio; scale bar= 10 µm. (A) Effect of MSN modulators on FAK activity of osteocytes; n=14. (B) 
Effect of MSN modulators on Src activity of osteocytes; n= 16. (C) Effect of MSN modulators 
on RhoA activity of osteocytes; n=16. (D) Effect of MSN modulators on FAK activity of cancer 
cells; n= 18. (E) Effect of MSN modulators on Src activity of cancer cells; n= 16. (F) Effect of 






We also evaluated the extracellular role of MSN modulators in these kinases activities in 
cancer cells [Fig. 3.6.]. We transfected mesenchymal stem cells (MSCs) with MSN modulators 
and then transferred condition medium (CM) of transfected MSN to cancer cells. MSN modulators 
became present in extracellular environment of cancer cells due to secretion of exosomes and 
soluble factors related to MSN by treated MSCs. CM of MSCs treated with MSN- increased Src 
basal activity in cancer cells 10%, but it did not affect FAK and RhoA activities. On the other 
hand, CM of MSCs treated with MSN+ decreased basal activities of FAK, RhoA and Src 5%, 
10%, 6% respectively comparing to normal media condition. Therefore, extracellular MSN+ and 
intracellular Si MSN could suppress migration cancer cells.  
 
Figure 3.6. Role of extracellular MSN in cancer cells; color bar represent FRET ratio; scale bar= 
10 µm. (A) Effect of MSN modulators on FAK activity of cancer cells; FRET ratio= FRET 
CFP/FRET YFP; n=20. (B) Effect of MSN modulators on Src activity of cancer cells; FRET 
ratio= FRET CFP/FRET YFP; n=17. (C) Effect of MSN modulators on FAK activity of cancer 
cells; FRET ratio= FRET YFP/FRET CFP; n=22; * p<0.05, ** p<0.01. 
 
On the other side, we evaluated the role of MSN modulators in interaction between 
osteocytes and breast cancer cells [Fig. 3.7]. As we already observed in our experiments, CM of 
osteocytes (b) reduced beta catenin activity in the nucleus of metastasized breast cancer cells 30% 
comparing to normal media. In this experiment, CM of osteocytes treated with MSN- (c) did not 
change beta catenin translocation to the nucleus comparing to CM without modulators although it 
still reduced beta catenin activity comparing to normal media. In addition, CM of osteocytes 
treated with MSN+ reduced beta catenin activity in cancer cells 10% comparing to both CM and 
CM with MSN-. Therefore, MSN+ in extracellular matrix of cancer cells could suppress 







Figure 3.7. Effect of CM of osteocytes treated with MSN modulators on beta catenin activity of 
cancer cells; *, # ,$ p<0.05, **, ## p<0.01, *** p<0.001; scale bar=10 µm; n=18. color bar 






















In this study we evaluated the role of AMPK in osteogenesis and tumor suppression as well as 
the role of MSN in tumor suppression. Using FRET-based biosensors and a fluorescence intensity-
based biosensor, we quantified the signaling activities of AMPK, FAK, Src, and RhoA as well as 
beta catenin translocation into the nucleus. We examined the role of global AMPK and 
mitochondria-specific AMPK in the signaling activities of osteocytes and pre-osteoblasts, and their 
interaction through osteocyte-based CM. Using CM for studying the interaction of osteocytes and 
breast cancer cells has been done in the other study [14]. An AMPK activator increased beta 
catenin translocation to the nucleus in both osteocytes and pre-osteoblasts although an AMPK 
inhibitor did not affect its activity. Interestingly, inhibition of Mito-AMPK increased beta catenin 
activity of osteocytes significantly which may cause secretion of soluble factors in favor of bone 
homeostasis and formation. However, inhibition of Mito-AMPK did not affect beta catenin activity 
of pre-osteoblast cells. Previous studies show the positive role of AMPK activation in 
osteogenesis. It is observed that Metformin as an AMPK activator drug can elevate the expression 
of BMP-2 as well as endothelial nitric oxide synthase (eNOS) in pre-osteoblasts causing 
osteoblastic differentiation and bone formation [41]. Moreover, an AMPK activator such as 
Metformin can cause pre-osteoblast cell differentiation through another pathway including Dlx5 
and Runx2 which are transcription factors for osteogenesis [42]. In addition, bone development 
treatment using Naringin employs AMPK for activation of Wnt signaling and beta catenin protein 
translocation to the nucleus in pre-osteoblast cells, leading to bone formation [45]. In addition, 
AMPK activation could hinder apoptosis of osteocyte cells by high homocysteine (Hcy) in blood 
plasma which is an important reason for osteoporosis [53, 54]. Our studies suggest that soluble 
factors secreted by osteocytes increased the beta catenin activity of pre-osteoblasts. Particularly, 
global AMPK activation and inhibition of Mito-AMPK could significantly increase the beta 
catenin activity of pre-osteoblast leading to osteoblast differentiation and osteogenesis. Activity of 
osteocytes could also affect the metastasized breast cancer in the bone; therefore, we evaluated the 
role of AMPK in cancer cells. Interestingly, osteocyte-derived CM reduced the beta catenin 
activity in cancer cell, and inhibition of Mito-AMPK in osteocytes further reduced the beta catenin 
activity in cancer cells. Therefore, inhibition of Mito-AMPK may not only suppress cancer 





Mechanical stress on bone is known to affect osteocytes and metastasized cancer progression. 
It has been reported that fluid flow stimulates cancer cell migration, but inhibition of Mito-AMPK 
suppresses the flow-induced cancer cell migration [61]. We observed that mechanical force 
increases AMPK activity and ROCK could act as an upstream of AMPK in osteocytes. Our 
observation is consistent with a published report that AMPK acts as an upstream kinase of RhoA 
in human breast cells when E-cadherin was experiencing the mechanical force [33]. Also, a study 
based on bioinformatics approach has revealed that AMPK is one of canonical signaling pathways 
in osteocytes under fluid flow stress [78]. It is also shown that ROCK inhibition in skeletal muscle 
cells activates AMPK and relieves the metabolic disorder [36].  
We show that CM derived from fluid flow-treated osteocytes increases beta-catenin activity in 
breast cancer cells. This may cause stimulation of tumor growth. Fluid flow treatment of osteocytes 
increased both global and mitochondrial AMPK activities in osteocyte, and we observed that CM 
of osteocytes treated with global AMPK activation or mitochondria-specific AMPK inhibition 
reduced beta catenin activity in cancer cells. Therefore, it is possible that Mito-AMPK inhibition 
in osteocytes may be able to decrease flow-induced elevation of beta catenin activity in cancer 
cells. In addition, in cancer cells global AMPK activation or Mito-AMPK inhibition decreased the 
activities of Rho family GTPases.  
We also examined the role of MSN in the activities of tumor-promoting proteins such as FAK, 
Src, and RhoA. In osteocytes partial silencing of MSN (MSN-) reduced RhoA and Src activities 
and increased FAK activity, while it reduced FAK and Src activities in cancer cells and did not 
significantly alter RhoA activity. Previous study showed that ROCK activated MSN in breast 
cancer cells leading to expression of programmed cell death ligand (PD-L1); thus, either ROCK 
inhibition or MSN silencing downregulated PD-L1 expression leading to penetration of immune 
cells in favor of cancer treatment [87].  
Moreover, we evaluated the role of extracellular MSN by using the CM of MSN-activated cells 
in cancer cells.  CM of MSCs treated with MSN+ reduced FAK, Src and RhoA activities in cancer 
cells. We reasoned that that MSCs treated with MSN modulators could secrete soluble factors and 
exosomes including MSN.  Our studies show that extracellular and intracellular MSN may have 
opposite effects on the activities of FAK and Src in cancer cells. In addition, we observed that CM 





causing suppression of tumor progression. Therefore, extracellular overexpression of MSN may 
have a positive role in preventing tumor progression by suppressing oncogenic proteins.     
In summary, our results suggest that inhibition of mitochondria-specific AMPK and/or 
activation of MSN in osteocytes may be used as a new therapeutic approach for cancer treatment. 
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